Just 14 stocks with market caps above $1 billion have doubled so far this year. They probably aren't the winners you would ...

Novo Nordisk NVO and Viking Therapeutics VKTX have emerged as notable players in the obesity space. A market leader in the ...

Research even suggests it can change users' sense of smell, and other common side effects include diarrhoea, nausea, 'sulphur ...

Whichever way the tariff winds blow (and I've no special knowledge of that), Novo Nordisk stock remains arguably the cheapest ...

The supply of GLP-1 drugs has been increasing, but they’re still expensive for most patients. Here are answers to some ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy.

Let's consider two corporations that could help you do better than average in the next decade: Eli Lilly (NYSE: LLY) and ...

An international study reveals that the drug can reverse liver damage in patients. An international study led by researchers ...

Despite Lars Fruergaard Jørgensen's resignation as Novo Nordisk's CEO, its stock price has risen 10% over the past two weeks.

Health insurance plans are changing how they cover GLP-1 drugs for weight loss to rein in costs, forcing doctors and patients ...

If you are looking to get a weight loss drug but lack insurance coverage, telehealth websites such as Ro, Hers and Mochi Health sell GLP-1 drugs for lower prices than what you’d pay at a pharmacy, ...

Compounding pharmacies, that produced the weight loss drugs at a fraction of their brand name price, are being forced to stop ...